文献速递细菌感染、耐药与抗菌药物医院感染防控

替加环素治疗多重耐药鲍曼不动杆菌肺炎的疗效与安全性:系统综述与荟萃分析

Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR Acinetobacter baumannii: a systematic review and meta-analysis.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

该系统综述与荟萃分析纳入1项前瞻性研究和9项回顾性研究,比较以替加环素为基础的方案与其他抗生素方案治疗鲍曼不动杆菌肺部感染。结果显示两组临床治愈率和死亡率相似,但替加环素组微生物清除率显著较低,肾毒性发生率显著低于以黏菌素为基础的方案。

要点

  • 替加环素方案治疗MDRAB肺炎的临床治愈率和死亡率与其他抗生素方案相似。
  • 替加环素组微生物清除率显著低于对照组。
  • 替加环素方案肾毒性发生率显著低于以黏菌素为基础的方案。

核心结论

  • 替加环素可用于治疗MDRAB肺部感染,疗效与其他抗生素相似,且未显示更高死亡风险。
  • 鉴于微生物清除率较低可能诱导耐药,仍需设计良好的RCT评估高剂量替加环素治疗AB肺炎。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Embase、Web of Science和Cochrane图书馆数据库至2019年3月12日。
  • 纳入比较以替加环素为基础方案与其他抗生素方案治疗AB肺部感染的研究,共1项前瞻性研究和9项回顾性研究。

主要发现

  • 替加环素组与对照组临床治愈率相似(OR=1.04,95%CI=0.60-1.81;P=0.89)。
  • 替加环素组与对照组死亡率相似(OR=1.11,95%CI=0.65-1.89;P=0.71)。
  • 替加环素组微生物清除率显著低于对照组(OR=0.43,95%CI=0.27-0.66;P=0.0001)。
  • 以替加环素为基础方案的肾毒性发生率显著低于以黏菌素为基础的方案(OR=0.34,95%CI=0.16-0.74,I2=35%,P=0.006)。

临床怎么用

  • MDRAB肺部感染可考虑使用替加环素,但需关注其较低的微生物清除率及潜在耐药诱导风险。
  • 对于需避免肾毒性的患者,替加环素方案可能优于以黏菌素为基础的方案。

局限性

  • 未纳入随机对照试验(RCT)。
  • 安全性数据不完整。
  • 多数研究来自中国,存在区域偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Use of tigecycline in treating MDR Acinetobacter baumannii (MDRAB) remains controversial. OBJECTIVES: To comprehensively assess the safety and efficacy of tigecycline in pneumonia caused by Acinetobacter baumannii. METHODS: PubMed, Embase, Web of Science and Cochrane library databases were searched up to 12 March 2019. Studies were included if they compared tigecycline-based regimens with other antibiotic regimens for treating AB pulmonary infections and we pooled the clinical outcomes, microbiological response, adverse events or mortality. RESULTS: One prospective study and nine retrospective studies were included in this meta-analysis. The results showed similar clinical cure rates (OR = 1.04, 95% CI = 0.60-1.81; P = 0.89) and mortality rates (OR = 1.11, 95% CI = 0.65-1.89; P = 0.71) comparing tigecycline groups with the control groups. However, a significantly lower microbiological eradication rate was found in the tigecycline groups (OR = 0.43, 95% CI = 0.27-0.66; P = 0.0001). Incidence of nephrotoxicity in tigecycline-based regimens was significantly lower than in colistin-based regimens (OR = 0.34, 95% CI = 0.16-0.74, I2 = 35%, P = 0.006). There were no randomized controlled trials (RCTs) included; incomplete safety data and regional bias caused by the majority of the studies originating in China are the main limitations of this meta-analysis. CONCLUSIONS: Tigecycline can be used for treating MDRAB pulmonary infections owing to efficacy similar to that of other antibiotics. Moreover, tigecycline did not show a higher risk of mortality. Considering the lower microbiological eradication rate for tigecycline, which is likely to induce antimicrobial resistance, well-designed RCTs for high-dose tigecycline in treating pneumonia caused by AB are still needed.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Mei H, Yang T, Wang J, et al. Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR Acinetobacter baumannii: a systematic review and meta-analysis. J Antimicrob Chemother. 2019. PMID: 31377765. doi:10.1093/jac/dkz337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。